Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

Balance Sheet: Liabilities and Stockholders’ Equity 
Quarterly Data

Amgen Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Accounts payable 1,908 2,147 2,267 1,628 1,590 1,358 1,212 1,320 1,572 1,204 1,256 1,403 1,366 1,171 1,277 1,396 1,421 1,161 1,150 1,338
Accrued liabilities 17,641 14,621 13,722 14,127 15,359 14,168 13,718 12,061 12,524 11,584 10,545 10,639 10,731 9,383 8,984 9,917 10,141 8,701 9,282 8,649
Current portion of long-term debt 3,550 3,544 5,528 3,959 1,443 1,428 2,167 834 1,591 1,543 817 844 87 4,288 4,324 1,556 91 91 91 1,840
Current liabilities 23,099 20,312 21,517 19,714 18,392 16,954 17,097 14,215 15,687 14,331 12,618 12,886 12,184 14,842 14,585 12,869 11,653 9,953 10,523 11,827
Long-term debt, excluding current portion 56,549 56,854 57,117 60,061 63,170 59,040 59,377 60,761 37,354 37,161 35,705 36,010 33,222 33,291 28,458 31,129 32,895 34,196 34,133 30,008
Long-term deferred tax liabilities 1,616 1,711 1,780 1,862 2,354
Long-term tax liabilities 2,349 2,280 2,205 3,964 4,680 4,579 4,478 5,864 5,757 5,680 5,603 6,652 6,594 6,483 6,428 7,037 6,968 7,560 7,556 8,111
Other noncurrent liabilities 2,349 2,199 2,363 2,357 2,326 2,305 2,536 2,532 2,662 2,875 2,949 2,732 2,465 2,160 2,055 2,170 2,023 1,969 2,140 2,238
Noncurrent liabilities 62,863 63,044 63,465 68,244 72,530 65,924 66,391 69,157 45,773 45,716 44,257 45,394 42,281 41,934 36,941 40,336 41,886 43,725 43,829 40,357
Total liabilities 85,962 83,356 84,982 87,958 90,922 82,878 83,488 83,372 61,460 60,047 56,875 58,280 54,465 56,776 51,526 53,205 53,539 53,678 54,352 52,184
Common stock and additional paid-in capital; $0.0001 par value 33,533 33,393 33,204 33,082 33,070 32,753 32,601 32,535 32,514 32,371 31,343 31,247 32,096 31,989 31,877 31,806 31,802 31,713 31,610 31,525
Accumulated deficit (27,590) (25,530) (27,124) (27,870) (26,549) (24,971) (25,540) (26,919) (28,622) (28,066) (28,252) (29,568) (24,600) (22,964) (22,762) (21,639) (21,408) (19,851) (20,168) (21,378)
Accumulated other comprehensive loss (66) (336) (155) (190) (289) (126) (280) (268) (231) (652) (672) (763) (796) (808) (868) (833) (985) (903) (783) (662)
Stockholders’ equity 5,877 7,527 5,925 5,022 6,232 7,656 6,781 5,348 3,661 3,653 2,419 916 6,700 8,217 8,247 9,334 9,409 10,959 10,659 9,485
Total liabilities and stockholders’ equity 91,839 90,883 90,907 92,980 97,154 90,534 90,269 88,720 65,121 63,700 59,294 59,196 61,165 64,993 59,773 62,539 62,948 64,637 65,011 61,669

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Amgen Inc. current liabilities decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Amgen Inc. noncurrent liabilities decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Amgen Inc. total liabilities decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Amgen Inc. stockholders’ equity increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.